Nezelof syndrome: Difference between revisions
No edit summary |
Gerald Chi- (talk | contribs) mNo edit summary |
||
| Line 1: | Line 1: | ||
{{Infobox_Disease | | {{Infobox_Disease | | ||
Name = {{PAGENAME}} | | Name = {{PAGENAME}} | | ||
| Line 13: | Line 12: | ||
MeshNumber = | | MeshNumber = | | ||
}} | }} | ||
__NOTOC__ | |||
{{SI}} | {{SI}} | ||
{{CMG}} | {{CMG}} | ||
'''Nezelof syndrome''' (also known as "Thymic dysplasia with normal immunoglobulins"<ref name="Andrews">{{cite book |author=James, William D. |author2=Berger, Timothy G.|title=Andrews' Diseases of the Skin: clinical Dermatology |publisher=Saunders Elsevier |location= |year=2006 |pages= |isbn=0-7216-2921-0 |oclc= |doi= |accessdate=|display-authors=etal}}</ref>{{rp|85}}) is an [[autosomal]] [[recessive]]<ref>{{OMIM|242700}}</ref> [[congenital]] [[immunodeficiency]] condition due to underdevelopment of the [[thymus]]. An association with [[CD44]] has been proposed.<ref name="pmid8734358">{{cite journal |vauthors=Knutsen AP, Wall D, Mueller KR, Bouhasin JD |title=Abnormal in vitro thymocyte differentiation in a patient with severe combined immunodeficiency-Nezelof's syndrome |journal=J. Clin. Immunol. |volume=16 |issue=3 |pages=151–8 |date=May 1996 |pmid=8734358 |doi= 10.1007/BF01540913|url=}}</ref> | |||
'''Nezelof syndrome''' ( | The defect is a type of [[purine nucleoside phosphorylase deficiency]] with inactive phosphorylase. This results in an accumulation of deoxy-GTP which inhibits ribonucleotide reductase. Ribonucleotide reductase catalyzes the formation of deoxyribonucleotides from ribonucleotides. Thus, DNA replication is inhibited and cells cannot replicate. | ||
==History== | |||
The disorder was characterized in 1964.<ref name="pmid14195287">{{cite journal |pmid=14195287 |date=Oct 1964 |vauthors=Nezelof C, Jammet ML, Lortholary P, Labrune B, Lamy M |title=Hereditary Thymic Hypoplasia: Its Place And Responsibility In A Case Of Lymphocytic, Normoplasmocytic And Normoglobulinemic Aplasia In An Infant |volume=21 |issue= |pages=897–920 |issn=0003-9764 |journal=Archives Françaises de Pédiatrie}}</ref> It is considered to be a form of [[combined immunodeficiency]] in [[ICD-10]] but a deficiency of [[cell-mediated immunity]] in [[ICD-9]]. | |||
==Presentation== | |||
It causes severe infections and malignancies. it is characterized by elevated immunoglobulins that function poorly. | |||
==Treatment== | |||
Treatment includes antimicrobial therapy, IV immunoglobulin, [[bone marrow transplantation]], [[thymus transplantation]] and thymus factors. | |||
== See also == | |||
* [[List of radiographic findings associated with cutaneous conditions]] | |||
== External links == | |||
* {{GPnotebook|1597308962}} | |||
== References == | |||
==References== | |||
{{reflist|2}} | {{reflist|2}} | ||
Revision as of 22:00, 3 June 2016
| Nezelof syndrome | |
| ICD-10 | D81.4 |
|---|---|
| ICD-9 | 279.13 |
| OMIM | 242700 |
| DiseasesDB | 29571 |
|
WikiDoc Resources for Nezelof syndrome |
|
Articles |
|---|
|
Most recent articles on Nezelof syndrome Most cited articles on Nezelof syndrome |
|
Media |
|
Powerpoint slides on Nezelof syndrome |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Nezelof syndrome at Clinical Trials.gov Trial results on Nezelof syndrome Clinical Trials on Nezelof syndrome at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Nezelof syndrome NICE Guidance on Nezelof syndrome
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Nezelof syndrome Discussion groups on Nezelof syndrome Patient Handouts on Nezelof syndrome Directions to Hospitals Treating Nezelof syndrome Risk calculators and risk factors for Nezelof syndrome
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Nezelof syndrome |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Nezelof syndrome (also known as "Thymic dysplasia with normal immunoglobulins"[1]:85) is an autosomal recessive[2] congenital immunodeficiency condition due to underdevelopment of the thymus. An association with CD44 has been proposed.[3]
The defect is a type of purine nucleoside phosphorylase deficiency with inactive phosphorylase. This results in an accumulation of deoxy-GTP which inhibits ribonucleotide reductase. Ribonucleotide reductase catalyzes the formation of deoxyribonucleotides from ribonucleotides. Thus, DNA replication is inhibited and cells cannot replicate.
History
The disorder was characterized in 1964.[4] It is considered to be a form of combined immunodeficiency in ICD-10 but a deficiency of cell-mediated immunity in ICD-9.
Presentation
It causes severe infections and malignancies. it is characterized by elevated immunoglobulins that function poorly.
Treatment
Treatment includes antimicrobial therapy, IV immunoglobulin, bone marrow transplantation, thymus transplantation and thymus factors.
See also
External links
References
- ↑ James, William D.; Berger, Timothy G.; et al. (2006). Andrews' Diseases of the Skin: clinical Dermatology. Saunders Elsevier. ISBN 0-7216-2921-0.
- ↑ Online Mendelian Inheritance in Man (OMIM) 242700
- ↑ Knutsen AP, Wall D, Mueller KR, Bouhasin JD (May 1996). "Abnormal in vitro thymocyte differentiation in a patient with severe combined immunodeficiency-Nezelof's syndrome". J. Clin. Immunol. 16 (3): 151–8. doi:10.1007/BF01540913. PMID 8734358.
- ↑ Nezelof C, Jammet ML, Lortholary P, Labrune B, Lamy M (Oct 1964). "Hereditary Thymic Hypoplasia: Its Place And Responsibility In A Case Of Lymphocytic, Normoplasmocytic And Normoglobulinemic Aplasia In An Infant". Archives Françaises de Pédiatrie. 21: 897–920. ISSN 0003-9764. PMID 14195287.